Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342117 · ClinicalTrials.gov registry record
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
A clinical trial, sponsored by SecuraBio.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04342117 is a clinical trial that was terminated before completion, run by SecuraBio. The registered enrollment target is 2 participants.
The verdict
NCT04342117 was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
Interventions
- DRUG duvelisib
- DRUG PI3K inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-23 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04342117
The ClinicalTrials.gov registry entry for NCT04342117 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which duvelisib is the first listed.
NCT04342117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04342117 about?
NCT04342117 is a clinical study titled "Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL". This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
What is the current status of trial NCT04342117?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2020-04-23. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04342117?
The interventions under investigation include: duvelisib (DRUG), PI3K inhibitor (DRUG).
Who is sponsoring clinical trial NCT04342117?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.